Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxapram in preterm newborns with apnea of prematurity
NL-OMON24880Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in apnea of prematurity (AOP) comparing Doxapram with Placebo (2 arms). Primary endpoint: Death or severe disability at 2 years corrected age. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
doxapram
03
Conditions
apnea of prematurity (AOP)
Beyond the preview
Go deeper on NL-OMON24880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24880.